<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002046</url>
  </required_header>
  <id_info>
    <org_study_id>014G</org_study_id>
    <secondary_id>18</secondary_id>
    <nct_id>NCT00002046</nct_id>
  </id_info>
  <brief_title>A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC</brief_title>
  <official_title>A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics of Retrovir (AZT) administered orally as 1 of 3 doses in the&#xD;
      treatment of patients with severe clinical and laboratory manifestations of HIV infection. To&#xD;
      compare the safety and tolerance of AZT administered 2, 3, and 6 x daily to these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Electron beam therapy to an area of less than 100 cm2.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Any immediately life-threatening infection or medical condition present at the time of&#xD;
             study entry.&#xD;
&#xD;
          -  Any active opportunistic or other infection requiring chronic therapy present at the&#xD;
             time of study entry.&#xD;
&#xD;
          -  Patients with Pneumocystis carinii pneumonia (PCP) may be randomized to study&#xD;
             medication following a minimum 7-day course of therapy resulting in stabilization of&#xD;
             their disease. Patients with stabilized disease must have fever &lt; 39 degrees C for at&#xD;
             least 48 hours; oxygen (on room air)&#xD;
&#xD;
             = or &gt; 60 mm, and arterial / alveolar gradient = or &lt; 30 mm.&#xD;
&#xD;
          -  Kaposi's sarcoma, lymphoma, or other tumor likely to require cytotoxic chemotherapy.&#xD;
&#xD;
        Seropositive for HIV antibody documented by any federally licensed ELISA.&#xD;
&#xD;
        Patients must have ability to give informed consent and advanced HIV disease defined as:&#xD;
&#xD;
        - History of Pneumocystis carinii pneumonia (PCP) with histologic verification within 4&#xD;
        months of study entry.&#xD;
&#xD;
        OR History of other opportunistic infection included in the CDC surveillance definition of&#xD;
        AIDS (stage IV-C-1), diagnosed within 4 months of entry, but not requiring chronic&#xD;
        suppressive therapy, and a CD4+ cell count &lt; 200 cells/mm3.&#xD;
&#xD;
        OR AIDS related complex (ARC) only those patients with a CD4+ count &lt; 200 cells/mm3 and&#xD;
        documentation of at least two signs or symptoms from the list below. One sign or symptom&#xD;
        must be weight loss or candidiasis as described.&#xD;
&#xD;
          -  Unexplained weight loss &gt; 10 percent or = or &gt; 15 lbs within the previous 4 months;&#xD;
             with low weight at entry.&#xD;
&#xD;
          -  History of mucocutaneous oral candidiasis (by culture or potassium hydroxide KOH&#xD;
             smear).&#xD;
&#xD;
          -  Fever &gt; 38 degrees C, without documented infectious cause present, persisting &gt; 1&#xD;
             month.&#xD;
&#xD;
          -  Oral hairy leukoplakia.&#xD;
&#xD;
          -  Unexplained night sweats, persisting &gt; 1 month.&#xD;
&#xD;
          -  Herpes zoster infection within 3 months of entry.&#xD;
&#xD;
          -  Chronic diarrhea of unknown infectious etiology persisting &gt; 1 month after 3 samples&#xD;
             have been done eliminating ova, parasites, Cryptosporidia, Mycobacterium avium&#xD;
             intracellulare, cytomegalovirus (CMV), and other pathogens associated with diarrheal&#xD;
             disease in AIDS patients.&#xD;
&#xD;
        Negative Venereal Disease Research Laboratory (VDRL) or Rapid Plasma Reagent (RPR) or, if&#xD;
        positive and verified by Fluorescent Treponemal Antibody Absorption (FTAABS), documented&#xD;
        history of treatment for syphilis. If FTAABS is positive, but treatment history is not&#xD;
        available, the patient may be entered 3 or more days following the initiation of&#xD;
        appropriate chemotherapy.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Chronic herpes virus infection.&#xD;
&#xD;
          -  Fever &gt; 39 degrees C at study entry.&#xD;
&#xD;
          -  Known hypersensitivity to lactate and/or gelatin.&#xD;
&#xD;
          -  Kaposi's sarcoma, lymphoma, or other tumor likely to require cytotoxic chemotherapy.&#xD;
&#xD;
          -  Impaired renal function.&#xD;
&#xD;
          -  AIDS dementia complex.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Drugs which cause significant bone marrow suppression.&#xD;
&#xD;
          -  Rifampin or rifampin derivatives.&#xD;
&#xD;
          -  Drugs which cause significant nephrotoxicity or hepatotoxicity.&#xD;
&#xD;
          -  Antiretroviral agents, including ribavirin, dideoxycytidine, dideoxyadenosine,&#xD;
             didanosine, foscarnet, dextran sulfate, and AL-721.&#xD;
&#xD;
          -  Acyclovir therapy of more than 21 days duration.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy (with the exception of electron beam therapy to an area of less than&#xD;
             100 cm2).&#xD;
&#xD;
          -  Experimental therapy.&#xD;
&#xD;
          -  Cytolytic chemotherapy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Acyclovir therapy of more than 21 days duration.&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Drugs which cause significant bone marrow suppression.&#xD;
&#xD;
          -  Rifampin or rifampin derivatives.&#xD;
&#xD;
          -  Drugs which cause significant nephrotoxicity or hepatotoxicity.&#xD;
&#xD;
          -  Immunomodulating agents, including pharmacologic doses of steroids for &gt; 10 days.&#xD;
&#xD;
          -  Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Interferon.&#xD;
&#xD;
          -  Isoprinosine.&#xD;
&#xD;
          -  IL-2.&#xD;
&#xD;
          -  Excluded within 8 weeks of study entry:&#xD;
&#xD;
          -  Antiretroviral agents, including ribavirin, dideoxycytidine, dideoxyadenosine,&#xD;
             didanosine, foscarnet, dextran sulfate, and AL-721.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy (with the exception of electron beam therapy to an area of less than&#xD;
             100 cm2).&#xD;
&#xD;
          -  Experimental therapy.&#xD;
&#xD;
          -  Cytolytic chemotherapy.&#xD;
&#xD;
        Active drug or alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of Arizona / Health Science Ctr</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Univ Med School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook County Hosp</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - Saint Luke's Med Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Missouri at Kansas City School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of New Mexico Hlth Sciences Ctr / Dept of Med</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore Hosp / Cornell Univ</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pennsylvania / HIV Clinic</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX Galveston Med Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 1990</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

